Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2258)

[DasTier666]

Hammer Volumen heute

hier der Link zur Januar Präsentation
http://novavax.com/download/files/presentation/36th_Annual_J…

Sollten dann noch die NanoFLu Daten in Februar überzeugen könnte es noch weiter gehen
http://ir.novavax.com/news-releases/news-release-details/nov…

[DasTier666]

Antwort auf Beitrag Nr.: 55.388.442 von Cyberhexe am 24.07.17 23:40:05

Sehe ich auch so. Nun noch eine neue PII, da wird's eng mit der Kohle.

[Cyberhexe]

Antwort auf Beitrag Nr.: 55.384.653 von DasTier666 am 24.07.17 15:16:29

Zitat von DasTier666: Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM

Preliminary webcast agenda:
1. Announce topline data from the Phase 2 safety and immunogenicity trial in Older Adults
2. Provide additional findings from prior Phase 2 and Phase 3 clinical trials in Older Adults
3. Update on the Prepare™ trial for Infants via Maternal Immunization

http://ir.novavax.com/news-releases/news-release-details/nov…

Na mal schauen, was die Jungs zu berichten haben. Vorbörse sieht gut aus, zur Zeit 7% im Grünen.

...da soll dem einfältigen Investor eine Mogelpackung verkauft werden: "positive topline data” jedoch nicht zu Wirksamkeit, lediglich Info zu Nebenwirkungen und Immunogenicity bei dieser gescheiterten ph2-Studie. Wer macht wann das Licht aus?

[DasTier666]

nur so am Rande

Genocea Reports Positive Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes
Jul 24, 2017

...
About GEN-003
Inducing a T cell response against genital herpes is critical to treating the clinical symptoms of disease and controlling transmission of the infection. GEN-003 is a first-in-class investigational T cell-directed immunotherapy designed to elicit both a T cell and B cell (antibody) immune response. The immunotherapy was designed using Genocea's ATLAS™ platform, which profiles the comprehensive spectrum of actual T cell responses mounted by humans in response to disease and identifies antigen targets that drive effective T cell responses. GEN-003 includes the antigens ICP4 and gD2 along with Matrix-M™ adjuvant (licensed from Novavax, Inc. (NASDAQ:NVAX)). For more information about GEN-003, please visit the GEN-003 section of the Genocea website.
...

http://ir.genocea.com/releasedetail.cfm?releaseid=1034082

[DasTier666]

Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM

Preliminary webcast agenda:
1. Announce topline data from the Phase 2 safety and immunogenicity trial in Older Adults
2. Provide additional findings from prior Phase 2 and Phase 3 clinical trials in Older Adults
3. Update on the Prepare™ trial for Infants via Maternal Immunization

http://ir.novavax.com/news-releases/news-release-details/nov…

Na mal schauen, was die Jungs zu berichten haben. Vorbörse sieht gut aus, zur Zeit 7% im Grünen.

[hn068]

starker Kursgewinn

NASDAQ und Lang & Schwarz machen heute bei Novavax weiter große Schritte nach oben.

[hn068]

Die Rückkehr - die Seitwärtsbewegung ist beendet

Die neuen Zahlen sprechen für sich und die bevorstehende Veröffentlichung lässt bei Insidern die Vermutung aufkommen, endlich sind die Testphasen erfolgreich verlaufen! Warum sollte Novavax denn auch sonst schon seit Tagen Gerüche streuen, dass die Herstellung der Impfstoffe direkt nach der Veröffentlichung beginnen könnte?!

[sandsack]

Antwort auf Beitrag Nr.: 55.135.025 von hn068 am 13.06.17 23:12:51

...scheinbar schon...

[hn068]

Gibt es noch Hoffung für Novavax?

[DasTier666]

Novavax RSV F Vaccine Phase 2 Clinical Trial Data in Women of Child Bearing Age Published in Vaccine
GAITHERSBURG, Md., June 7, 2017

...
The manuscript documents the significant antibody response elicited by the RSV F Vaccine, including 11.6 to 12.7-fold increases in anti-F IgG responses in women receiving a single dose of 120 µg RSV F Vaccine with 0.2 or 0.4 mg of aluminum. These antibody responses peaked 14 days post-vaccination and persisted at significantly elevated levels for the 3 month period during which immunogenicity was evaluated. Palivizumab-competing antibody (PCA) levels were low or undetectable at day 0 but increased to 341-423 µg/mL on day 14 for the 120 µg 1-dose regimens. While baseline levels of RSV/A and RSV/B microneutralizing titers did not vary in the placebo group, they more than doubled at day 28 against both RSV strains for the 120 µg, 0.4 mg aluminum formulation, which the Company selected for further development.
Importantly, confirming results from the Company's prior trial in a similar population, serologic evidence of a new RSV infection by Western Blot was present in 21% (18/84) of placebo recipients, compared to only 10% (36/352) of vaccinees, a 52% (p=0.009) overall reduction of infection.
...
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…


Sieht endlich mal wieder gut aus.